{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.06","upperLimit":"85.40","value":"73.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"In addition, responses were assessed by CRC based on MLN IWG response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.","id":"OG000","title":"Pemigatinib 13.5 mg"}],"paramType":"NUMBER","populationDescription":"Full Efficacy-Evaluable Population. Confidence intervals were calculated based on the exact method for binomial distribution.","reportingStatus":"POSTED","timeFrame":"up to 2513 days (120 21-day treatment cycles)","title":"Percentage of Participants Who Achieved a CCyR as Assessed by CRC Assessment","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}